Samsung Biologics Co.,Ltd. (207940.KS)

732.000,00 +3.000,00 (+0,41%) Al cierre: 03:30PM KST

Samsung Biologics Co.,Ltd.

300, Songdobio-daero
Yeonsu-gu
Incheon 21987
South Korea
82 3 2455 3114
https://samsungbiologics.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. John Chongbo Rim	CEO, President & Chairman of Board	3,12B	N/A	1961
Mr. Dong-Joong Kim	CFO, Executive VP, MD & Director	666M	N/A	1965
Mr. Pierre Catignol	Executive VP & Head of Operation Center	N/A	N/A	1968
Dr. Namjin Chung Ph.D.	Executive VP and Head of Bio R&D Centre & CSO	N/A	N/A	N/A
Mr. James J. Choi	Executive VP, Head of CDO Development Center & Head of Sales Center	569M	N/A	1967
Mr. Kyuho Lee	Executive VP, Head of People Center, & Chief Human Resource Officer	N/A	N/A	N/A
Dr. Brian Hosung Min Ph.D.	Executive VP & Head of CDO Development Center	N/A	N/A	N/A
Mr. Doyoung Heo	Vice President & Head of Finance	N/A	N/A	1975
Mr. Heekyun Lim	VP & Head of Business Consulting Team	N/A	N/A	1975
Dr. Kun Lo Ph.D.	Executive VP, Head of EPCV Center & Director	N/A	N/A	1963

Los importes son a partir de 31 de diciembre de 2021 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en KRW.

Descripción

Samsung Biologics Co.,Ltd. engages in the contract development and manufacturing organization (CDMO) business for biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates in two segments, CDMO, and Biopharmaceutical Development and Commercialization. Its development services include discovery, cell line development, process development, and clinical manufacturing. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the research and commercialization of biosimilar drugs; development and manufacture of antibody-drug conjugates; and manufactures mammalian and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.

Gobierno corporativo

El ISS Governance QualityScore de Samsung Biologics Co.,Ltd., a día 1 de junio de 2024, es 5. Las puntuaciones base son Auditoría: 1; Tablero: 5; Derechos de los accionistas: 4; Compensación: 7.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.